OCGN - Ocugen slips as accounting errors force restatements
2024-04-02 11:19:08 ET
More on Ocugen
- Ocugen: A Speculative Buy In Biotech Growing Clinical Trials To Billion-Dollar Revenues
- Ocugen shares make gains after US court dismisses class action lawsuits
- Ocugen hits a 52-week high after decision to lower quorum requirement
- Seeking Alpha’s Quant Rating on Ocugen
- Historical earnings data for Ocugen